Company intelligence / Profile preview
Aelix Therapeutics
Barcelona, Catalonia, Spainaelixtherapeutics.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Clinical-stage biotech developing therapeutic HIV vaccines. Recent Phase II trials (AELIX-002/003) demonstrated safety and prolonged viral suppression without antiretrovirals when combining HTI vaccine with Gilead's TLR7 agonist vesatolimod.
- Therapeutic areas
- Infectious Diseases
- Modalities
- DNA vaccineTherapeutic vaccineViral vector vaccines (MVA, ChAdOx1)Small molecule drug combinations
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Aelix Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aelix Therapeutics.